Skip to main content

Cardlytics Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

CDLX$1.63-10.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows (Unaudited)

Nine Months EndedSeptember 30,
20242023
Operating activities
Net Loss$(173,715)$(33,866)
Adjustments to reconcile net loss to net cash used in operating activities:
Credit loss expense3,9801,153
Depreciation and amortization19,74919,765
Amortization of financing costs charged to interest expense1,2351,234
Amortization of right-of-use assets1,6272,807
Gain on debt extinguishment(13,017)—
Stock-based compensation expense31,69429,956
Impairment of goodwill and intangible assets131,595—
Change in contingent consideration110(15,044)
Other non-cash income, net(4,136)(613)
Change in operating assets and liabilities:
Accounts receivable12,90910,991
Prepaid expenses and other assets(229)1,114
Accounts payable820(265)
Other accrued expenses(3,192)(10,282)
Partner Share liability(18,330)(4,994)
Consumer Incentive liability(2,903)(5,075)
Net cash used in operating activities(11,803)(3,119)
Investing activities
Acquisition of property and equipment(1,439)(393)
Capitalized software development costs(13,423)(8,302)
Business divestiture202—
Net cash used in investing activities(14,660)(8,695)
Financing activities
Proceeds from issuance of debt172,50030,000
Settlement of contingent consideration(14,167)(50,050)
Principal payment of debt(199,291)(21)
Proceeds from termination of capped calls related to convertible notes115—
Proceeds from issuance of common stock48,63455
Equity issuance costs(309)(58)
Debt issuance costs(5,836)—
Net cash provided by (used in) financing activities1,646(20,074)
Effect of exchange rates on cash, cash equivalents and restricted cash(25)43
Net decrease in cash, cash equivalents and restricted cash(24,842)(31,845)
Cash, cash equivalents, and restricted cash — Beginning of period91,830121,985
Cash, cash equivalents, and restricted cash — End of period$66,988$90,140

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Nine Months EndedSeptember 30,
20242023
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:
Cash and cash equivalents$66,988$90,067
Restricted cash—73
Total cash, cash equivalents and restricted cash — End of period$66,988$90,140
Supplemental disclosure of cash flow information:
Cash paid for interest$2,453$2,958
Amounts accrued for property and equipment$20$—
Amounts accrued for capitalized software development costs$203$—
Issuance of common stock, net of issuance costs - Settlement Agreement (as defined below)$27,451$—
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.